CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; none of the 61 sources its claims cite is checked for support yet.

TMEM119+ microglia MHC class I restricted antigen presentation impacts CD8 T cell memory, effector status, and blood-brain barrier disruption during neurotropic virus infection

Open access

Abstract

The impact of microglia antigen presentation on CNS infiltrating CD8 T cells responses during neurotropic virus infection remains undefined. Using Theiler’s murine encephalomyelitis virus (TMEV) infection of neurons as a model system, we generated H-2K b and H-2D b Tmem119 conditional knockout mice. During TMEV infection, we determined using Tmem119 K b cKO mice that microglia H-2K b contributes to antiviral CD8 T cell proliferation in the brain. Meanwhile, using Tmem119 D b cKO mice we determined that microglia H-2D b increased antiviral CD8 T cell perforin levels and the capacity to induce blood-brain barrier (BBB) disruption. Furthermore, microglial H-2D b was essential for antigen-specific reactivation of CD8 tissue resident memory (TRM) cell recall responses and BBB disruption long after virus had been cleared. These findings demonstrate discrete roles of individual MHC class I genes on microglia in CD8 T cell proliferation, effector functions, memory recall and neuropathology.

Overview

CoChat Summary

TL;DR

Using Tmem119-CreERT2 conditional knockout mice for H-2Kb or H-2Db, this study shows that microglial MHC class I molecules have discrete roles during TMEV infection: microglial H-2Kb supports CD8 T cell proliferation in the brain, while microglial H-2Db promotes perforin expression, blood-brain barrier disruption, and CD8 tissue-resident memory recall. The effects are CNS-localized and, for memory recall, occur long after virus clearance.

Key findings

  • In TMEV-OVA infection, Tmem119 Kb cKO mice had a marked reduction in Kb:OVA epitope-specific CD8 T cells in the brain at 7 days post-infection; BrdU/FTY720 experiments showed decreased BrdU+ and antiviral Kb:OVA CD8 T cells, indicating microglial H-2Kb is required for optimal CD8 T cell proliferation in the brain. Parabiosis with a Cre− littermate did not restore these reductions, indicating the stimulation occurs within the brain.
  • In TMEV infection, Tmem119 Db cKO mice at 7 days post-infection showed no change in Db:VP2121–130 tetramer+ CD8 T cell frequencies, but had reduced perforin protein levels and reduced percentages of perforin+ CD8 T cells and Db:VP2121–130 tetramer+ CD8 T cells. In the peptide-induced fatal syndrome model, Tmem119 Db cKO mice had reduced infiltrating CD45hi cells, total T cells, CD8 T cells, and Db:VP2121–130 tetramer+ CD8 T cells, plus reduced FITC-albumin leakage; parabiosis did not restore BBB disruption.
  • At 30 days post-infection, Tmem119 Db cKO and Cre− controls had similar numbers of Db:VP2121–130 tetramer+ CD8 T cells and CD69+CD103+ cells. After peptide reactivation, however, Tmem119 Db cKO mice showed decreased Db:VP2121–130 tetramer+ CD8 T cell expansion, reduced total infiltrating CD45hi cells and CD11b+MHC II+ myeloid cells, and reduced gadolinium leakage by MRI when the CD8 TRM response was isolated with FTY720.

Methods

  • Generated tamoxifen-inducible Tmem119-CreERT2 × H-2Kb fl/fl or H-2Db fl/fl conditional knockout mice; used 10–15-week-old male and female mice with age- and sex-matched controls. Tamoxifen was given at 75 mg/kg i.p. at 8 weeks for 5 consecutive days for Kb cKO mice, or 5 days followed by 1 week recovery and 5 additional days for Db cKO mice.
  • Infected mice intracranially with TMEV Daniel’s strain (2 × 10^6 PFU) or TMEV-OVA (2 × 10^5 PFU). Analyzed brain-infiltrating leukocytes by spectral flow cytometry at 7 days post-infection or later, using FTY720, BrdU, intravascular CD45 labeling, FITC-albumin leakage, MRI, parabiosis, and peptide reactivation with VP2121–130 or control E7 peptide.
  • Statistics used unpaired or paired Student’s t-tests, one-way ANOVA with Tukey’s post hoc test, or two-way ANOVA with Šidák’s test; analyses performed in Prism 10.0, Excel, or R; data presented as mean ± SD.

Limitations

  • Stated in the paper: the mechanisms underlying microglial antigen presentation are still unknown; it is unclear whether modulation of perforin and BBB damage would be beneficial in different disease models; future studies are needed to investigate this form of regulation; and more studies are needed to confirm the dynamics in other disease models.
  • Evident from the text: many results are described qualitatively in the prose (e.g., “marked reduction,” “no differences”) without numeric effect sizes or confidence intervals, though figures contain quantification not available in the provided text.
  • Evident from the text: although male and female mice were used, no sex-specific analyses or differences are reported; the text also identifies itself as a preprint with supplementary files.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.21203/rs.3.rs-10061124/v1

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Development of TMEM119+ microglia MHC class I molecule conditional knockout mice. Graphs in gray and pink represent Tmem119 Kb cKO mice and Cre-littermate controls. Graphs in orange and red represent Tmem119 Db cKO mice and Cre-littermate controls. (A) Representative histograms and percentages of Kb expression of TMEM119+ cells in the brain in Tmem119 Kb cKO mice compared to Cre- littermate controls 7 days post TMEV infection, followed by (B) H-2Kb expression in several immune cell populations in the blood. (C) Representative histograms and percentages of Db expression of TMEM119+ cells in the brain in Tmem119 Db cKO mice compared to Cre-littermate controls 7 days post TMEV infection, followed by (D) H-2Db expression in several immune cell populations in the blood. (E, F) Splenic TCR repertoire is not affected by cell-specific H-2Kb and H-2Db deletion. Splenocytes were isolated from naïve 10-week-old animals (N = 3–7 per group) and stained with anti-CD45, anti-TCRβ, anti-CD4, and anti-CD8 antibodies, as well as antibodies specific to each of the T-cell receptor Vβ regions listed. (G, H) Representative plots and quantification show no disruption of thymocyte development in Tmem119 Kb cKO mice and Tmem119 Db cKO in comparison to Cre negative littermates. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 1. Development of TMEM119+ microglia MHC class I molecule conditional knockout mice. Graphs in gray and pink represent Tmem119 Kb cKO mice and Cre-littermate controls. Graphs in orange and red represent Tmem119 Db cKO mice and Cre-littermate controls. (A) Representative histograms and percentages of Kb expression of TMEM119+ cells in the brain in Tmem119 Kb cKO mice compared to Cre- littermate controls 7 days post TMEV infection, followed by (B) H-2Kb expression in several immune cell populations in the blood. (C) Representative histograms and percentages of Db expression of TMEM119+ cells in the brain in Tmem119 Db cKO mice compared to Cre-littermate controls 7 days post TMEV infection, followed by (D) H-2Db expression in several immune cell populations in the blood. (E, F) Splenic TCR repertoire is not affected by cell-specific H-2Kb and H-2Db deletion. Splenocytes were isolated from naïve 10-week-old animals (N = 3–7 per group) and stained with anti-CD45, anti-TCRβ, anti-CD4, and anti-CD8 antibodies, as well as antibodies specific to each of the T-cell receptor Vβ regions listed. (G, H) Representative plots and quantification show no disruption of thymocyte development in Tmem119 Kb cKO mice and Tmem119 Db cKO in comparison to Cre negative littermates. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central
Figure 2. Tmem119 Kb cKO mice exhibit decreased Kb:OVA epitope specific CD8 T cell numbers and decreased BrdU labeling at brain 7 days post TMEV-OVA infection. (A) Schematic depicting the Cre-LoxP strategy. Tmem119-CreERT2 mice were crossed to transgenic H-2Kb LoxP mice. (B) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day. Mice were infected with TMEV-OVA and euthanized 7 days post infection. Brains were analyzed using spectral flow cytometry. (C) Representative uniform manifold approximation and projection (UMAP) key, colored to highlight the different cell subsets in the brain for both Kb Cre-Littermate and Tmem119-CreERT2 Kb cKO mice. (D) Absolute counts of CD45hi, T cells, CD8 T cells and Kb:OVA Tetramer+ CD8 T cells per brain. (E) Experimental design showing mice were treated with FTY720 or water twice a day starting 4 days after TMEV-OVA infection. 5 days after TMEV-OVA infection, mice received an IP injection of BrdU. Mice were euthanized 7 days after TMEV-OVA infection and perfused. Brains were analyzed using a Cytek Aurora. (F) Bar charts show reduced % BrdU in T cells, CD8 T cells and Kb:OVA Tetramer+ cells in Tmem119 Kb cKO mice compared to cre-littermate controls, as well as representative histograms for Brdu expression in Kb:OVA Tetramer+ cells. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 2. Tmem119 Kb cKO mice exhibit decreased Kb:OVA epitope specific CD8 T cell numbers and decreased BrdU labeling at brain 7 days post TMEV-OVA infection. (A) Schematic depicting the Cre-LoxP strategy. Tmem119-CreERT2 mice were crossed to transgenic H-2Kb LoxP mice. (B) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day. Mice were infected with TMEV-OVA and euthanized 7 days post infection. Brains were analyzed using spectral flow cytometry. (C) Representative uniform manifold approximation and projection (UMAP) key, colored to highlight the different cell subsets in the brain for both Kb Cre-Littermate and Tmem119-CreERT2 Kb cKO mice. (D) Absolute counts of CD45hi, T cells, CD8 T cells and Kb:OVA Tetramer+ CD8 T cells per brain. (E) Experimental design showing mice were treated with FTY720 or water twice a day starting 4 days after TMEV-OVA infection. 5 days after TMEV-OVA infection, mice received an IP injection of BrdU. Mice were euthanized 7 days after TMEV-OVA infection and perfused. Brains were analyzed using a Cytek Aurora. (F) Bar charts show reduced % BrdU in T cells, CD8 T cells and Kb:OVA Tetramer+ cells in Tmem119 Kb cKO mice compared to cre-littermate controls, as well as representative histograms for Brdu expression in Kb:OVA Tetramer+ cells. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central
Figure 3. CD8 T cell expansion in the brain is governed by microglia Kb restricted antigen presentation and not through peripheral circulating factors. (A) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day. A Tmem119 Kb cKO mouse was then attached to a Cre- littermate through parabiosis surgery. 3 weeks later, mice were infected with TMEV-OVA and euthanized 7 days post infection. Brains were analyzed using spectral flow cytometry. (B) Absolute counts of CD45hi, T cells, CD8 T cells and Kb:OVA Tetramer+ CD8 T cells per brain. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 3. CD8 T cell expansion in the brain is governed by microglia Kb restricted antigen presentation and not through peripheral circulating factors. (A) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day. A Tmem119 Kb cKO mouse was then attached to a Cre- littermate through parabiosis surgery. 3 weeks later, mice were infected with TMEV-OVA and euthanized 7 days post infection. Brains were analyzed using spectral flow cytometry. (B) Absolute counts of CD45hi, T cells, CD8 T cells and Kb:OVA Tetramer+ CD8 T cells per brain. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central
Figure 4. Tmem119 Db cKO mice have decreased perforin expression by CD8 T cells 7 days post TMEV infection. (A) Schematic depicting the Cre-LoxP strategy. Tmem119-CreERT2 mice were crossed to transgenic H-2Db LoxP mice. (B) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day. After 1 week, another 5 days of tamoxifen injections were employed. Mice were then infected with TMEV and euthanized 7 days post infection. Brains were analyzed using a Cytek Aurora. (C) Representative uniform manifold approximation and projection (UMAP) key, colored to highlight the different cell subsets in the brain for both Db Cre- Littermate and Tmem119-CreERT2 Db cKO mice. (D) Absolute counts of CD45hi, T cells, CD8 T cells and Db:VP2121–130 Tetramer+ CD8 T cells per brain are displayed in the bar charts, as well as frequency of perforin on CD8 T cells and Db:VP2121–130 Tetramer+ cells. (E) Percentages of Perforin+ cells of Db:VP2121–130 Tetramer+ CD8 T cells are displayed in the bar charts, followed by graph displaying MFI of perforin on of Db:VP2121–130 Tetramer+ CD8 T cells and a histogram of a representative sample for Perforin expression on Db:VP2121–130 Tetramer+ CD8 T cells (scaled to Unit Area to normalize by area and not number of events). Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 4. Tmem119 Db cKO mice have decreased perforin expression by CD8 T cells 7 days post TMEV infection. (A) Schematic depicting the Cre-LoxP strategy. Tmem119-CreERT2 mice were crossed to transgenic H-2Db LoxP mice. (B) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day. After 1 week, another 5 days of tamoxifen injections were employed. Mice were then infected with TMEV and euthanized 7 days post infection. Brains were analyzed using a Cytek Aurora. (C) Representative uniform manifold approximation and projection (UMAP) key, colored to highlight the different cell subsets in the brain for both Db Cre- Littermate and Tmem119-CreERT2 Db cKO mice. (D) Absolute counts of CD45hi, T cells, CD8 T cells and Db:VP2121–130 Tetramer+ CD8 T cells per brain are displayed in the bar charts, as well as frequency of perforin on CD8 T cells and Db:VP2121–130 Tetramer+ cells. (E) Percentages of Perforin+ cells of Db:VP2121–130 Tetramer+ CD8 T cells are displayed in the bar charts, followed by graph displaying MFI of perforin on of Db:VP2121–130 Tetramer+ CD8 T cells and a histogram of a representative sample for Perforin expression on Db:VP2121–130 Tetramer+ CD8 T cells (scaled to Unit Area to normalize by area and not number of events). Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central
Figure 5. Peptide-induced fatal syndrome elicits increased cell infiltration in comparison to Tmem119 Db cKO mice. (A) Mice were intracranially infected with TMEV. 7 days later, mice received the TMEV immunodominant peptide VP2121–130 intravenously. Injection of VP2121–130 peptide will induce lethal blood-brain barrier. 12 hours post injection of VP2121–130, mice were euthanized, perfused, and analyzed. (B) Absolute counts of CD45hi, T cells, CD8 T cells and Db:VP2121–130 Tetramer+ CD8 T cells per brain are displayed in the bar charts. (C) Mice were intracranially infected with TMEV. 7 days later, mice received the TMEV immunodominant peptide VP2121–130 intravenously. 11 hours after the VP2121–130 injection, FITC-albumin was administered intravenously. 12 hours post injection of VP2121–130, mice were euthanized and analyzed. (D) Representative sagittal images of FITC-albumin injected mice 12 hours post VP2121–130 injection, displaying BBB leakage differences between Cre+ and Cre− groups. Quantification is displayed on the left. Scale bar = 2 mm. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 5. Peptide-induced fatal syndrome elicits increased cell infiltration in comparison to Tmem119 Db cKO mice. (A) Mice were intracranially infected with TMEV. 7 days later, mice received the TMEV immunodominant peptide VP2121–130 intravenously. Injection of VP2121–130 peptide will induce lethal blood-brain barrier. 12 hours post injection of VP2121–130, mice were euthanized, perfused, and analyzed. (B) Absolute counts of CD45hi, T cells, CD8 T cells and Db:VP2121–130 Tetramer+ CD8 T cells per brain are displayed in the bar charts. (C) Mice were intracranially infected with TMEV. 7 days later, mice received the TMEV immunodominant peptide VP2121–130 intravenously. 11 hours after the VP2121–130 injection, FITC-albumin was administered intravenously. 12 hours post injection of VP2121–130, mice were euthanized and analyzed. (D) Representative sagittal images of FITC-albumin injected mice 12 hours post VP2121–130 injection, displaying BBB leakage differences between Cre+ and Cre− groups. Quantification is displayed on the left. Scale bar = 2 mm. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central
Figure 6. Tmem119 Db cKO mice are protected from BBB disruption despite sharing circulation with a Cre- littermate parabiont. (A) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day, and then another 5 days 1 week later. A Tmem119 Db cKO mouse was then attached to a Cre- littermate through parabiosis surgery. 3 weeks later, mice were infected with TMEV. 7 days later, mice received the TMEV immunodominant peptide VP2121–130 intravenously. 11 hours after the VP2121–130 injection, FITC-albumin was administered intravenously. 12 hours post injection of VP2121–130, mice were euthanized and analyzed. (B) Representative sagittal images of FITC-albumin injected mice 12 hours post VP2121–130 injection, displaying BBB leakage differences between Cre+ and Cre- groups. Quantification is displayed on the left. Scale bar = 2 mm. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 6. Tmem119 Db cKO mice are protected from BBB disruption despite sharing circulation with a Cre- littermate parabiont. (A) Experimental design showing mice were treated with tamoxifen to activate cre for 5 days, once a day, and then another 5 days 1 week later. A Tmem119 Db cKO mouse was then attached to a Cre- littermate through parabiosis surgery. 3 weeks later, mice were infected with TMEV. 7 days later, mice received the TMEV immunodominant peptide VP2121–130 intravenously. 11 hours after the VP2121–130 injection, FITC-albumin was administered intravenously. 12 hours post injection of VP2121–130, mice were euthanized and analyzed. (B) Representative sagittal images of FITC-albumin injected mice 12 hours post VP2121–130 injection, displaying BBB leakage differences between Cre+ and Cre- groups. Quantification is displayed on the left. Scale bar = 2 mm. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central
Figure 7. Microglia Db restricted antigen presentation is not required for CD8 TRM cell formation in comparison to Cre- littermates. However, upon secondary challenge, Tmem119 Db cKO mice have attenuated immune cell infiltration. (A) Experimental design showing mice were treated with tamoxifen to activate cre recombinase for 5 days, once a day, and then another 5 days 1 week later. Mice were intracranially infected with TMEV and allowed 45 days for resolution of the infection and TRM generation. Mice were then euthanized, perfused, and analyzed. (B) Absolute counts of CD45hi, T cells, CD8 T cells and Db:VP2121–130 Tetramer+ CD8 T cells per brain are displayed in the bar charts. (C) Mice were intracranially infected with TMEV and allowed 30 days for resolution of the infection and TRM generation. Later, mice were treated with tamoxifen to activate cre recombinase for 5 days, once a day, and then another 5 days 1 week later. Following tamoxifen injections, mice received either the TMEV immunodominant peptide VP2121–130, or irrelevant peptide E7 two days before euthanasia. Injection of VP2121–130 peptide will reactivate TMEV specific T cells including TRMs in the brain. 24 hours post VP2121–130 injections mice received an intravenous injection of BV711 anti-CD45 conjugated antibody to label CD45+ cells within the blood circulation. 24 hours post injection of antibodies, mice were euthanized, perfused, and analyzed. (D) Absolute counts of infiltrating cells (CD45hi CD45-IV+ cells per brain) and myeloid cells (CD11b+ MHC II+ cells per brain). (E) Absolute counts of Db: VP2121–130 Tetramer+ CD8 T cells per brain. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 7. Microglia Db restricted antigen presentation is not required for CD8 TRM cell formation in comparison to Cre- littermates. However, upon secondary challenge, Tmem119 Db cKO mice have attenuated immune cell infiltration. (A) Experimental design showing mice were treated with tamoxifen to activate cre recombinase for 5 days, once a day, and then another 5 days 1 week later. Mice were intracranially infected with TMEV and allowed 45 days for resolution of the infection and TRM generation. Mice were then euthanized, perfused, and analyzed. (B) Absolute counts of CD45hi, T cells, CD8 T cells and Db:VP2121–130 Tetramer+ CD8 T cells per brain are displayed in the bar charts. (C) Mice were intracranially infected with TMEV and allowed 30 days for resolution of the infection and TRM generation. Later, mice were treated with tamoxifen to activate cre recombinase for 5 days, once a day, and then another 5 days 1 week later. Following tamoxifen injections, mice received either the TMEV immunodominant peptide VP2121–130, or irrelevant peptide E7 two days before euthanasia. Injection of VP2121–130 peptide will reactivate TMEV specific T cells including TRMs in the brain. 24 hours post VP2121–130 injections mice received an intravenous injection of BV711 anti-CD45 conjugated antibody to label CD45+ cells within the blood circulation. 24 hours post injection of antibodies, mice were euthanized, perfused, and analyzed. (D) Absolute counts of infiltrating cells (CD45hi CD45-IV+ cells per brain) and myeloid cells (CD11b+ MHC II+ cells per brain). (E) Absolute counts of Db: VP2121–130 Tetramer+ CD8 T cells per brain. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central
Figure 8. CD8 TRM cell responses are decreased in Tmem119 Db cKO mice and accompanied by reduced numbers of infiltrating cells and BBB permeability. (A) Experimental design showing mice were intracranially infected with TMEV and allowed 30 days for resolution of the infection and TRM generation. Later, mice were treated with tamoxifen to activate cre recombinase for 5 days, once a day, and then another 5 days 1 week later. Following tamoxifen injections, mice received an intravenous injection of the TMEV immunodominant peptide VP2121–130 to reactivate TMEV specific T cells including CD8 TRMs in the brain. 3 days before and 1 day after VP2121–130 injections, mice received intraperitoneal injections of FTY720 twice a day. 48 hours post VP2121–130 injections, mice were imaged using T1 gadolinium enganced MRIs and then euthanized, perfused, and analyzed. (B) UMAPs displaying frequencies of alive of several immune cell populations are displayed. (C) Absolute counts of infiltrating cells (#CD45hi+ cells) and myeloid cells (#CD11b+ MHC II+ cells) per brain, as well as (D) counts and numbers of Db:VP2121–130 Tetramer+ cells are displayed. (E) BBB permeability was measured by gadolinium enhanced MRIs analysis using T1 weighted MRIs. Representative images are displayed on the left followed by quantification on the right. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.
Figure 8. CD8 TRM cell responses are decreased in Tmem119 Db cKO mice and accompanied by reduced numbers of infiltrating cells and BBB permeability. (A) Experimental design showing mice were intracranially infected with TMEV and allowed 30 days for resolution of the infection and TRM generation. Later, mice were treated with tamoxifen to activate cre recombinase for 5 days, once a day, and then another 5 days 1 week later. Following tamoxifen injections, mice received an intravenous injection of the TMEV immunodominant peptide VP2121–130 to reactivate TMEV specific T cells including CD8 TRMs in the brain. 3 days before and 1 day after VP2121–130 injections, mice received intraperitoneal injections of FTY720 twice a day. 48 hours post VP2121–130 injections, mice were imaged using T1 gadolinium enganced MRIs and then euthanized, perfused, and analyzed. (B) UMAPs displaying frequencies of alive of several immune cell populations are displayed. (C) Absolute counts of infiltrating cells (#CD45hi+ cells) and myeloid cells (#CD11b+ MHC II+ cells) per brain, as well as (D) counts and numbers of Db:VP2121–130 Tetramer+ cells are displayed. (E) BBB permeability was measured by gadolinium enhanced MRIs analysis using T1 weighted MRIs. Representative images are displayed on the left followed by quantification on the right. Designation of symbols is as follows: ns or not shown for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001. Data presented as mean +/− SD.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 35 Not checked · 85 Own results and interpretations

68 more claims

Create a free account to see all 120 claims and to verify the 58 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 60 references

Cited by

Still being checked.

Metadata

Authors
Johnson, A., Seady, M., Maynes, M., Thelwell, J., Jin, F., Hansen, M., Jensen, H., Witter, R., Owens, C., Hassani, A., Lewis, C., & Forston, M.
Affiliations
Mayo Clinic (US)
Corresponding author
Johnson, Aaron
Venue
Research Square
Published
2026-06-24
OpenAlex
W7160888065
Cited by
0
References
59
Type
posted content
Language
en
Open access
Locations
  • Research Square (submittedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (submittedVersion)
  • PubMed Central (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (T32AI170478)
  • National Institute of Neurological Disorders and Stroke (R01NS122174, R01NS103212)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
TMEM119, microglia, MHC class I antigen presentation, H-2Kb, H-2Db, CD8+ T cells, tissue-resident memory T cells, Theiler's murine encephalomyelitis virus, blood-brain barrier disruption, perforin, conditional knockout mice, CNS immune response

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TMEM119+ microglia MHC class I restricted antigen presentation impacts CD8 T cell memory, effector status, and blood-brain barrier disruption during neurotropic virus infection. https://app.cochat.ai/papers/10.21203/rs.3.rs-10061124/v1
The paper
Johnson, A., Seady, M., Maynes, M., Thelwell, J., Jin, F., Hansen, M., Jensen, H., Witter, R., Owens, C., Hassani, A., Lewis, C., & Forston, M. (2026). TMEM119+ microglia MHC class I restricted antigen presentation impacts CD8 T cell memory, effector status, and blood-brain barrier disruption during neurotropic virus infection. Research Square. https://doi.org/10.21203/rs.3.rs-10061124/v1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.